FDA Expands Marstacimab Indication in Hemophilia A and B - Takeaways - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

  • By

  • Kathryn Wighton

  • June 8, 2026

Share

  • 1

    The FDA approved marstacimab-hncq (HYMPAVZI) for routine prophylaxis in hemophilia A and B patients aged 6 years and older.

  • 2

    HYMPAVZI is the first subcutaneous non-factor therapy for pediatric patients aged 6 to 11 years with hemophilia B.

  • 3

    In the phase 3 BASIS trial, marstacimab reduced the mean annualized bleeding rate by 93% compared to on-demand intravenous treatment.

  • 4

    Marstacimab targets the Kunitz 2 domain of tissue factor pathway inhibitor to restore balance between bleeding and coagulation.

  • 5

    Common adverse reactions include injection-site reactions, headache, and pyrexia, with warnings for thromboembolic events and hypersensitivity.

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Strengthening early relational health: strategies and system-level considerations for pediatric primary care

Measles Renews Focus on Vaccine Waivers

“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”

Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"